【News】Journal published on the effect of Cybernics Treatment for ALS


CYBERDYNE Inc. (Tsukuba, Ibaraki, Japan, President & CEO: Yoshiyuki Sankai) announced today that the results of its research on the HAL for Medical Use Lower Limb Type (hereafter “Medical HAL”) had been published in the online edition of the Journal of Clinical Neuroscience*1. A research group from Toho University School of Medicine has conducted one phase (total of nine sessions, 2-3 sessions per week, 1-2 months) of Cybernics Treatment*2 with Medical HAL and found the treatment method to be effective for improving the walking function of Amyotrophic Lateral Sclerosis (“ALS”) patients, a progressive neurodegenerative where no effective treatment methods were available to prevent the muscles from getting weaker.

For further information, please visit the following link